Bluejay Diagnostics Inc Dossier
Qualitative Analysis
Business overview
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a clinical-stage medical diagnostics company focused on improving patient outcomes in critical care settings. The company's core business centers on its proprietary Symphony technology platform, a rapid, near-patient testing system designed to deliver laboratory-quality results from whole blood samples in approximately 20 to 24 minutes. Bluejay's lead product candidate is the Symphony IL-6 test, which measures Interleukin-6 (IL-6) to support sepsis risk assessment, triage, and critical-care decision-making. The company is pre-revenue and is actively conducting clinical trials to support a 510(k) regulatory submission to the U.S. Food and Drug Administration (FDA).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Conducting a pivotal clinical trial to evaluate the predictive performance of IL-6 levels in ICU patients for 28-day all-cause mortality using the Symphony platform.
Expected impact: Validates the clinical utility of the Symphony IL-6 test to support a 510(k) FDA regulatory submission.
Establishing domestic, scalable manufacturing capabilities in the United States to reduce reliance on overseas manufacturing, mitigate import tariff risks, and improve operational flexibility.
Expected impact: Ensures regulatory-grade supply chain readiness, business continuity, and domestic distribution capabilities for commercial launch.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Establishes scalable, U.S.-based manufacturing and distribution capabilities for the Symphony platform, mitigating risks associated with overseas manufacturing and international sourcing.
Terms: Specific financial terms were not disclosed in the partnership announcement.
Serves as the contract manufacturing organization (CMO) for the Symphony analyzer, helping to scale manufacturing and supply chain readiness.
Terms: Governed by an amended Master Service Agreement and Master Supply Agreement.
Secures the transfer of manufacturing know-how and final supply obligations, strengthening Bluejay's independence in future cartridge manufacturing.
Terms: Amended on July 23, 2025, extending the timeline to establish alternate cartridge manufacturing to October 2026.